Viridian Therapeutics, Inc. DE (NASDAQ:VRDN)
| Market Cap | $3.46B+7.0% |
| Revenue (ttm) | $26.31M-62.8% |
| Net Income | -$453.58M-50.2% |
| EPS | -$3.87-19.1% |
| Shares Out | 113.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,951,091 |
| Open | $31.05 |
| Previous Close | $31.25 |
| Day's Range | $30.31 - $31.25 |
| 52-Week Range | $13.18 - $34.29 |
| Beta | 0.96 |
| Analysts | Buy |
| Price Target | $37.00(+21.39%) |
| Earnings Date | Feb 25, 2027 |
About VRDN
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
8 firms rating VRDN in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 25, 2027Earnings report
$VRDN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in VRDN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VRDN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VRDN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
VRDN Revenue by Segment
| Product revenue, net | $24.67M | 88.05% |
| Other income, net | $2.27M | 8.09% |
| Collaboration revenue | $956.00K | 3.41% |
| License revenue | $125.00K | 0.45% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New VRDN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VRDN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VRDN
| XBIState Street SPDR S&P Biotech ETF | $82.36M |
| IWMiShares Russell 2000 ETF | $81.27M |
| VTIVanguard Morningstar Total Stock Market ETF | $69.26M |
| IWNiShares Russell 2000 Value ETF | $26.53M |
| VXFVanguard Extended Market ETF | $26.40M |
| DFASDimensional - US Small Cap ETF | $21.34M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from VRDN’s recent data — informational, not investment advice
What’s Behind the Score
News check: Multiple analyst upgrades, positive Phase 1 clinical data for VRDN-008, and successful product launch tempered by one valuation concern.
Recent Insider Activity
Insider Score Trend Over Time
-39.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| SBIO | ALPS Medical Breakthroughs ETF | 2.26% |
| LFSC | F/M Emerald Life Sciences Innovation ETF | 1.87% |
| TDNA | T. Rowe Price Biotech ETF | 1.50% |
| BBC | Virtus Biotech Clinical Trials ETF | 1.41% |
| IWC | iShares Micro-Cap ETF | 0.77% |
| ILDR | First Trust Innovation Leaders ETF | 0.72% |
| BMED | iShares Health Innovation Active ETF | 0.65% |
| FYC | First Trust Small Cap Growth AlphaDEX Fund | 0.56% |
| SEIS | SEI Exchange Traded Funds - SEI Select Small Cap ETF | 0.23% |
| TMSL | T. Rowe Price Small-Mid Cap ETF | 0.21% |
| TNXT | T. Rowe Price Innovation Leaders ETF | 0.20% |
| IWN | iShares Russell 2000 Value ETF | 0.19% |
Weight is the stock’s share of each fund’s holdings.